Patents by Inventor Raymond T. Bartus

Raymond T. Bartus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11833185
    Abstract: Therapeutic peptides of the following sequence are disclosed: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, and optionally further comprising Xaa6, wherein Xaa represents an amino acid; Xaa3 is proline; and subscripts represent the positions of each amino acid in the peptide sequence starting from the amino terminus of said peptide extending to the C-terminus. A therapeutic peptide optionally includes a linker that cyclizes the peptide. Also described are methods of treating a neurodegenerative disorder and/or injury in a human subject in need of such treatment by administering to the subject a therapeutically effective amount of a therapeutic peptide as disclosed herein.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: December 5, 2023
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Luke H. Bradley, Don M. Gash, Greg A. Gerhardt, Raymond T. Bartus, Sr.
  • Publication number: 20210260149
    Abstract: Therapeutic peptides of the following sequence are disclosed: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, and optionally further comprising Xaa6, wherein Xaa represents an amino acid; Xaa3 is proline; and subscripts represent the positions of each amino acid in the peptide sequence starting from the amino terminus of said peptide extending to the C-terminus. A therapeutic peptide optionally includes a linker that cyclizes the peptide. Also described are methods of treating a neurodegenerative disorder and/or injury in a human subject in need of such treatment by administering to the subject a therapeutically effective amount of a therapeutic peptide as disclosed herein.
    Type: Application
    Filed: February 11, 2020
    Publication date: August 26, 2021
    Inventors: Luke H. Bradley, Don M. Gash, Greg A. Gerhardt, Raymond T. Bartus, SR.
  • Publication number: 20210008038
    Abstract: The present invention provides methods for parenterally administering riluzole to subjects in need of treatment.
    Type: Application
    Filed: February 13, 2020
    Publication date: January 14, 2021
    Inventors: Alexandre Betourne, Nicholas M. Boulis, Raymond T. Bartus
  • Publication number: 20200282007
    Abstract: Therapeutic peptides of the following sequence are disclosed: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, and optionally further comprising Xaa6, wherein Xaa represents an amino acid; Xaa3 is proline; and subscripts represent the positions of each amino acid in the peptide sequence starting from the amino terminus of said peptide extending to the C-terminus. A therapeutic peptide optionally includes a linker that cyclizes the peptide. Also described are methods of treating a neurodegenerative disorder and/or injury in a human subject in need of such treatment by administering to the subject a therapeutically effective amount of a therapeutic peptide as disclosed herein.
    Type: Application
    Filed: February 11, 2020
    Publication date: September 10, 2020
    Inventors: Luke H. Bradley, Don M. Gash, Greg A. Gerhardt, Raymond T. Bartus, SR.
  • Publication number: 20190269660
    Abstract: The present invention provides methods for parenterally administering riluzole to subjects in need of treatment.
    Type: Application
    Filed: March 13, 2019
    Publication date: September 5, 2019
    Inventors: Alexandre Betourne, Nicholas M. Boulis, Raymond T. Bartus
  • Patent number: 10322114
    Abstract: The present invention provides methods for parenterally administering riluzole to subjects in need of treatment.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: June 18, 2019
    Assignees: Above and Beyond NB, LLC, Emory University
    Inventors: Alexandre Betourne, Nicholas M Boulis, Raymond T Bartus
  • Publication number: 20190030007
    Abstract: The present invention provides methods for parenterally administering riluzole to subjects in need of treatment.
    Type: Application
    Filed: July 31, 2017
    Publication date: January 31, 2019
    Inventors: Alexandre Betourne, Nicholas M. Boulis, Raymond T. Bartus
  • Publication number: 20180055800
    Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
    Type: Application
    Filed: April 6, 2017
    Publication date: March 1, 2018
    Inventors: Blair C. Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
  • Publication number: 20160058727
    Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
    Type: Application
    Filed: September 10, 2015
    Publication date: March 3, 2016
    Inventors: Blair C. Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
  • Patent number: 9155699
    Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: October 13, 2015
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Blair C. Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
  • Publication number: 20140193501
    Abstract: A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm3. In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 10, 2014
    Applicant: Civitas Therapeutics, Inc.
    Inventors: Raymond T. Bartus, Dwaine F. Emerich
  • Publication number: 20140105983
    Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
    Type: Application
    Filed: October 17, 2013
    Publication date: April 17, 2014
    Applicant: Civitas Therapeutics, Inc.
    Inventors: Blair C. Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
  • Patent number: 8586093
    Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: November 19, 2013
    Assignee: Civitas Therapeutics
    Inventors: Blair Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
  • Patent number: 8420619
    Abstract: The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth factor such as neurotrophin-4 (NT4) is used to transduce cells of the retinal ganglion cell (RGC) layer, in situ, via administration of the vector intravitreally. Accordingly, methods are disclosed for treating subjects in need thereof by therapeutic protein delivery via a recombinant expression vector, including rescue of photoreceptors by targeting the RGC layer subpopulation of retinal cells.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: April 16, 2013
    Assignee: Ceregene, Inc.
    Inventors: Raymond T. Bartus, Kathie M. Bishop, Mehdi Gasmi
  • Patent number: 8404276
    Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: March 26, 2013
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Blair Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich
  • Publication number: 20120316112
    Abstract: The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth factor such as neurotrophin-4 (NT4) is used to transduce cells of the retinal ganglion cell (RGC) layer, in situ, via administration of the vector intravitreally. Accordingly, methods are disclosed for treating subjects in need thereof by therapeutic protein delivery via a recombinant expression vector, including rescue of photoreceptors by targeting the RGC layer subpopulation of retinal cells.
    Type: Application
    Filed: August 17, 2011
    Publication date: December 13, 2012
    Inventors: Raymond T. Bartus, Kathie M. Bishop, Mehdi Gasmi
  • Patent number: 8242093
    Abstract: The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth factor such as neurotrophin-4 (NT4) is used to transduce cells of the retinal ganglion cell (RGC) layer, in situ, via administration of the vector intravitreally. Accordingly, methods are disclosed for treating subjects in need thereof by therapeutic protein delivery via a recombinant expression vector, including rescue of photoreceptors by targeting the RGC layer subpopulation of retinal cells.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: August 14, 2012
    Assignee: Ceregene, Inc.
    Inventors: Raymond T. Bartus, Kathie M. Bishop, Mehdi Gasmi
  • Publication number: 20120087952
    Abstract: A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm3. In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others.
    Type: Application
    Filed: September 13, 2011
    Publication date: April 12, 2012
    Applicant: Civitas Therapeutics, Inc.
    Inventors: Raymond T. Bartus, Dwaine F. Emerich
  • Publication number: 20120082650
    Abstract: A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease. The protocol is practiced by directly delivering a definite concentration of a nerve growth factor via delivery of the protein, an expression vector operably encoding the nerve growth factor, or grafting a donor cell containing such an expression vector into the substantia nigra and preferably also the striatum. The method stimulates growth of targeted neurons, and reversal of functional deficits associated with the neurodegenerative disease being treated.
    Type: Application
    Filed: April 1, 2011
    Publication date: April 5, 2012
    Applicant: Ceregene, Inc.
    Inventors: Raymond T. Bartus, Joao Siffert
  • Patent number: RE43711
    Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: October 2, 2012
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Blair Jackson, David J. Bennett, Raymond T. Bartus, Dwaine F. Emerich